晚期非小细胞肺癌药物治疗进展.pdf

2014 12116 Chinese Journal of Drug Application and Monitoring, Vol.11, No.6, December 2014 1 1,2 1. 100853 2. 300100 [] [] [ ]R979.1 [ ]A [ ]1672 8157(2014)06 0329 05 New progress of drug therapy in advanced non-small cell lung cancer 1 1,2(1. Medical Oncology Department of PLA General Hospital, Beijing 100853, China; 2. School of Medicine, Nankai HU Yi , TAO Hai-tao University, Tianjin 300100, China) [ABSTRACT]Lung cancer is the leading cause of cancer mortality. Due to the progress in molecular target therapy, great progress has been achieved in advanced non-small cell lung cancer (NSCLC). Many treatments have been demonstrated to improve the objective remission rate, quality of life and even the progressive free survival and overall survival in translational researches. Traditional chemotherapy is very important for NSCLC patients, especially for those wild-type or unknown gene mutation patients; the progress in molecular target therapy just revolutionize the treatment of NSCLC and become the fi rst choice for those patients with gene sensitive mutation; the progresses of drugs which target specifi c checkpoint of immune system have led the immunotherapy to new heights, immunotherapy become the new choice for NSCLC. No matter chemotherapy, target therapy or immunotherapy, the treatments based on exact change of the molecular pathogenesis are the development direction of NSCLC. [KEY WORDS]Non-small cell lung cancer; Chemotherapy; Molecular target therapy; Immunotherapy [1] IPASSOPTIMAL non-small cell lung cancer NSCLC 85% CT 2013 Science Nivolumab NSCLC